Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGM-2644 in Relapsed/Refractory Multiple Myeloma
NCT05908396Phase 1Terminated
- Sponsor
- IGM Biosciences
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of IGM-2644 in multiple myeloma (MM) (2 arms), sponsored by IGM Biosciences. Primary endpoint: Safety and tolerability including MTD/MAD. Started Aug 2023; status: terminated.
02
Drugs
IGM-2644
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05908396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908396.